What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

Shaping the future of 177Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?

Annals of Oncology | November 7, 2025 | A.A. Azad, M.S. Hofman

Lutetium-177 prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy has rapidly established itself as a potent and well-tolerated treatment for metastatic castration-resistant prostate cancer (mCRPC). Early compassionate use,1 a phase II study,2 the TheraP3,4 and the landmark VISION trial5 established the efficacy of 177Lu-PSMA-617 in mCRPC previously treated with docetaxel. This led to global regulatory approval and adoption in the therapeutic armamentarium…

Topics: prostate-cancer, chemotherapy, breakthrough-drugs, clinical-trials, research

Read the full article at Annals of Oncology